Mouse Anti-DYRK1B Recombinant Antibody (2E8) (V2LY-0425-LY1155)

Bhat, N., Narayanan, A., Fathzadeh, M., Kahn, M., Zhang, D., Goedeke, L., ... & Mani, A. (2022). Dyrk1b promotes hepatic lipogenesis by bypassing canonical insulin signaling and directly activating mTORC2 in mice. The Journal of Clinical Investigation, 132(3).

Zhuang, L., Jia, K., Chen, C., Li, Z., Zhao, J., Hu, J., ... & Yan, X. (2022). DYRK1B-STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation, 145(11), 829-846.

Bhat, N., Narayanan, A., Fathzadeh, M., Shah, K., Dianatpour, M., Abou Ziki, M. D., & Mani, A. (2022). Dyrk1b promotes autophagy during skeletal muscle differentiation by upregulating 4e-bp1. Cellular Signalling, 90, 110186.

Papenfuss, M., Lützow, S., Wilms, G., Babendreyer, A., Flaßhoff, M., Kunick, C., & Becker, W. (2022). Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B. Scientific reports, 12(1), 1-15.

Lee Walmsley, D., Murray, J. B., Dokurno, P., Massey, A. J., Benwell, K., Fiumana, A., ... & Hubbard, R. E. (2021). Fragment-derived selective inhibitors of dual-specificity kinases DYRK1A and DYRK1B. Journal of Medicinal Chemistry, 64(13), 8971-8991.

Dong, C., An, L., Yu, C. H., & Huen, M. S. (2021). A DYRK1B-dependent pathway suppresses rDNA transcription in response to DNA damage. Nucleic acids research, 49(3), 1485-1496.

Chang, C. C., Chiu, C. C., Liu, P. F., Wu, C. H., Tseng, Y. C., Lee, C. H., & Shu, C. W. (2021). Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells. Cancers, 13(22), 5779.

Dong, C., West, K. L., Tan, X. Y., Li, J., Ishibashi, T., Yu, C. H., ... & Huen, M. S. (2020). Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin. Proceedings of the National Academy of Sciences, 117(29), 17019-17030.

Yousefelahiyeh, M., Xu, J., Alvarado, E., Yu, Y., Salven, D., & Nissen, R. M. (2018). DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B. PloS one, 13(11), e0207779.

Becker, W. (2018). A wake‐up call to quiescent cancer cells–potential use of DYRK 1B inhibitors in cancer therapy. The FEBS Journal, 285(7), 1203-1211.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols